Xenon Pharmaceuticals Inc. Share Price & Technical Analysis
XENE · $54.17 (+0.09%)
Healthcare / Biotechnology
$54.17
+0.09%
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures…
Price chart
Seasonality
May has 0 positive and 5 negative years (last 5 years shown)
-4% return in May, -12% avg return in past 3 year May month.
25% return in 2026, 8% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -9% | 5% | 37% | -4% | -4% | – | – | – | – | – | – | – | 25% |
| 25 | 2% | -6% | -10% | 14% | -24% | 8% | -2% | 28% | 3% | 5% | 7% | 0% | 24% |
| 24 | -1% | 4% | -13% | -6% | -8% | 1% | 11% | -6% | -2% | 1% | 3% | -8% | -23% |
| 23 | -1% | 1% | -10% | 14% | -4% | 0% | -4% | 6% | -13% | -10% | 17% | 29% | 24% |
| 22 | -13% | 17% | -3% | -8% | -6% | 15% | 10% | 17% | -6% | 1% | 0% | 6% | 29% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$5.33B
P/E ratio
—
52W high
$63.95
52W low
$28.19
Volume
9,24,498
Beta
0.65
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Xenon Pharmaceuticals Inc. share price today?
- Xenon Pharmaceuticals Inc. (XENE) last traded around $54.17 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does XENE have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for XENE. Download the app for real-time alerts.
- How can I analyze Xenon Pharmaceuticals Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.